Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1453687 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $7.42Day −3.01%Mkt cap $218M1Y −44.6%Off 52W high −46.8%Vol (1Y) 90.9%
Daily closing price, split-adjusted to the current basis; 2.7y shown of 672 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest6.6% of sh out |
| Days to cover12.3d |
| 13F net flow (QoQ)+7.08% |
| Top-10 13F concentration78.2% |
| Next report (est.)2026-07-30 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$1.8M |
| Earnings (TTM)-$151.8M |
| Net margin−4658.6% |
| Sales growth 3Y−70.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+2.9% |
| 1Y−44.6% |
| Since incept. (ann.)−41.8% |
Price return through 2026-07-29 · series begins 2023-11-14. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)90.9% |
| Ann. volatility (3Y)101.4% |
| Sharpe (1Y)−0.26 |
| Sharpe (3Y)−0.04 |
| Max drawdown (1Y)−57.4% |
| Max drawdown (3Y)−85.6% |
| Beta (3Y vs SPY)0.72 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Squarepoint Ops LLC | 2.2M | $14M | 7.62% | +12190.6% |
| FMR LLC | 799,743 | $5M | 2.72% | −41.5% |
| BlackRock, Inc. | 599,108 | $4M | 2.04% | −1.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 407,597 | $3M | 1.39% | new |
| 683 Capital Management, LLC | 330,000 | $2M | 1.12% | +17.9% |
| MILLENNIUM MANAGEMENT LLC | 284,317 | $2M | 0.97% | +73.0% |
| GEODE CAPITAL MANAGEMENT, LLC | 263,694 | $2M | 0.90% | +3.2% |
| MARSHALL WACE, LLP | 251,115 | $2M | 0.85% | +41.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-30 | −$1.46 | — | $78,000 | −92.9% |
| 2025-12-31 | 2026-03-09 | — | — | $947,000 | — |
| 2025-09-30 | 2025-11-06 | −$1.38 | — | $452,000 | +16.8% |
| 2025-06-30 | 2025-08-07 | $0.50 | −7.4% | $298,000 | −99.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-07-30 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Operating 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
